Overactive bladder and urinary incontinence

  • Value dossier for a treatment in stress urinary incontinence
  • HTA review and analysis for urinary incontinence
  • Abstracts, posters and a manuscript on the content validity of a patient bladder diary and the incontinence quality of life questionnaire
  • Further qualitative development of the incontinence quality of life questionnaire
  • Development of a PRO report on quality of life in urinary incontinence
  • Development of a regulatory dossier and claims assistance in idiopathic overactive bladder (OAB) with urinary urge incontinence
  • Recommendations for obtaining EMEA claims on the Incontinence Quality of Life Questionnaire (I-QOL) and the King’s Health Questionnaire (KHQ)
  • Content validation and psychometric validation of the Kings Health Questionnaire in incontinent OAB patients
  • Development of a PRO dossier for the FDA to support the King’s Health Questionnaire on OAB
  • Content validation and psychometric validation of an incontinence questionnaire for patients
  • Content validation of the patient bladder diary for OAB with urinary urge incontinence
  • Health outcomes appendices for phase III neurogenic OAB studies
  • Development and validation of a clinical screening tool for OAB in multiple sclerosis
  • Advisory board for a clinical screening tool for OAB in multiple sclerosis
  • Publications from the tool development and validation projects of OAB in multiple sclerosis
  • Development of health outcomes appendices in idiopathic OAB
  • Preference evaluation to compare treatments for OAB
  • Mode of administration study in an OAB population
  • Economic dossier on an antispasmodic, anticholinergic agent for OAB
  • Review of screening tools in OAB
  • Item pooling for OAB
  • Development of a screener for OAB based on a pragmatic approach and item pooling
  • SAP, analysis, report and manuscript on the OAB-S questionnaire
  • Standalone validation study in treatment-naive OAB patients
  • Development of a tool for ranking the importance of OAB symptoms and the achievement of treatment goals
  • Review of data and promotional claim strategy in OAB
  • Cognitive debriefing of an OAB questionnaire
  • Linguistic validation of a natural remedy for OAB
  • Phase I disease progression study of OAB in Sweden
  • Development of a patient satisfaction questionnaire in OAB
  • Validation of the Overactive Bladder Satisfaction (OAB-S) Questionnaire
  • Support activity on the OAB-S questionnaire
  • Development of a briefing package in relation to the concept of urinary urgency
  • FDA meeting attendance on the development of a briefing package in relation to the concept of urinary urgency
  • Cognitive debriefing of a new PRO assessment for urinary urgency
  • Worldwide advisory board on a treatment for OAB